TABLE 4.
Odds ratios (OR) of clinically relevant weight gain (≥7%), early weight change (≥5% within 30 days) and new onset of other metabolic abnormalities in function of olanzapine doses
| Metabolic disturbance onset | n | Associations with olanzapine daily dose, OR (95% CI) | Associations with high daily dose of olanzapine (>10 mg/day), OR (95% CI) |
|---|---|---|---|
| CRW | 377 | 2.21 (0.35–14.1) | 1.55 (0.93–2.59) |
| EWC | 377 | 12.7 (3.78–43.1) * | 2.15 (1.57–2.94) * |
| Obesity (>30 kg/m2) | 283 | 1.38 (0.01–152) | 2.37 (0.81–6.89) |
| Elevated fasting plasma glucose (≥5.6 mmol/L) | NC | NC | |
| Hypertriglyceridaemia (>1.7 mmol/L) | NC | NC | |
| Total hypercholesterolaemia (≥5 mmol/L) | 149 | 0.00 (0.00–574) | 1.06 (0.05–21.5) |
| HDL hypocholesterolaemia (≥1.29 mmol/L in women/≥1.03 mmol/L in men) | 170 | 4.81 (0.00–42 857) | 0.53 (0.06–4.80) |
| Hypertension (SBP ≥ 85mmgHg & DBP ≥ 130 mmHg) | 38 | 0.53 (0.00–59.2) | 0.68 (0.15–3.02) |
| Metabolic Syndrome | NC | NC |
Abbreviations: CI, confidence interval; CRW, clinically relevant weight gain (≥7%); DBP, diastolic blood pressure; EWC, early weight change (≥5% within 30 days); HDL, high‐density lipoprotein; NC, not calculated; OR, odds ratio; SBP, systolic blood pressure.
*
p < 0.001.